Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.68 |
| ▸ | GAK | O14976 | 3/20 | 0.63 |
| ▸ | FBP1 | P09467 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.58 |
| ▸ | BUB1 | O43683 | 2/20 | 0.58 |
| ▸ | STK10 | O94804 | 2/20 | 0.58 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.58 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.58 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.58 |
| ▸ | CARS1 | P49589 | 1/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.57 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.57 |
| ▸ | AURKA | O14965 | 2/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.57 |
| ▸ | PLK4 | O00444 | 1/20 | 0.57 |
| ▸ | CIT | O14578 | 1/20 | 0.57 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.57 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7539320 | 0.85 | EGFR (0.66) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL29484155 | 0.85 | EGFR (0.69) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL28407487 | 0.85 | EGFR (0.69) | EGFRGAKFBP1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL7535035 | 0.84 | EGFR (0.65) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL7981320 | 0.82 | EGFR (0.73) | EGFRERBB2ABCG2DAPK3ABL1 | |
| SCHEMBL809971 | 0.81 | EGFR (0.67) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL7978403 | 0.81 | EGFR (0.73) | EGFRFBP1ALDH1A1MAPTERBB2 | |
| SCHEMBL2988440 | 0.81 | EGFR (1.00) | EGFRFBP1ERBB2ABCG2MKNK1 | |
| SCHEMBL7975392 | 0.81 | EGFR (0.73) | EGFRERBB2 | |
| SCHEMBL1766075 | 0.81 | EGFR (0.64) | EGFRGAKFBP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3031807-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | Auckland UniServices Limited (NZ) | 2016-06-15 | — | — | EP | disclosed |
| EP-2406262-B1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2016-02-17 | — | — | EP | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | EGFR 48/4885GAK 413/4885FBP1 3114/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | EGFR 41/4885GAK 534/4885FBP1 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.